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2) A large number of derivatives of MTX have been synthesized in an attempt to obtain more effective compounds against solid tumors than MTX.
3) These efforts have led to the discovery of several promising compounds 4a) such as trimetrexate, edatrexate, lometrexol and tomudex (ZD-1694). 4b) We previously reported that N- [4-[3- (2,4-diamino-7H-pyrrolo [2,3-d] pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid (1b, TNP-351), a novel dihydrofolate reductase (DHFR) inhibitor characterized by the presence of a pyrrolo [2,3-d] pyrimidine ring, showed potent antitumor activities against not only leukemia cells but also various solid tumor cells both in vitro 5) and in vivo. 6) Biological evaluation of TNP-351 has demonstrated that it is more efficiently taken up by tumor cells via the reduced folate carrier (RFC) system and is much more rapidly converted to polyglutamates than MTX, 6) and that the formed polyglutamates were potent inhibitors of aminoimidazolecarboxamide ribonucleotide transformylase 7) as well as DHFR. 8) As an extension of our research, we have made modifications to the glutamic acid moiety of TNP-351, as shown in Fig. 1 . Replacement of the a-or g-carboxyl group of the glutamic acid by a tetrazolyl group suggested that the a-carboxyl group plays an important role in effective uptake via the RFC-mediated transport system, and that the g-carboxyl group moiety is important for tight binding to DHFR. 9) In our previous paper, we reported that non-glutamate type antifolates containing N 5 -substituted glutamines (2) were potent inhibitors of DHFR and active against some murine tumor cells and MTX-resistant human CCRF-CEM cells. 1) Based on our previous results, we designed N w -masked ornithine analogs (9, 11, 14, 18, 21, 23, 25, 30, 36) of TNP-351 and its related compound (1a) as novel non-glutamate type antifolates, that were expected to be transported effectively into cells via the RFC due to the existence of a a-carboxyl group and to be potent inhibitors of DHFR because of optimization of the g-carboxyl group moiety of the glutamic acid residue.
In this paper, we describe the preparation of novel nonglutamate type pyrrolo [2,3-d] pyrimidine antifolates (9, 11, 14, 18, 21, 23, 25, 30, 36) with N w -masked 2,w-diaminoalkanoic acid in place of glutamic acid, together with their inhibitory effects on DHFR and the growth of murine Meth A cells and some MTX-resistant human CCRF-CEM cells in culture.
Chemistry Pyrrolo [2,3-d] pyrimidine carboxylic acids 7a, b were synthesized by our previously reported method. 10) Most pyrrolo [2,3-d] pyrimidine antifolates containing acylornithines were prepared by one of two methods; the first is coupling of 7a, b and N d -acylornithine esters (6, 12, 16) and subsequent hydrolysis (method A), and the other is acylation of free amino ornithinate analogs 19, key intermediates derived from N d -tert-butoxycarbonyl (Boc)-ornithine antifolates (17) and subsequent hydrolysis (method B) ( Table 1) . Synthesis of hemiphthaloyl ornithine analogs (9) and benzyloxycarbonyl (Z)-or Boc-ornithine analogs (14, 18) were performed using method A, and the other acylornithine analogs (21) and sulfonyl analogs (23, 25) were prepared using method B. In the case of hemiphthaloyl ornithine analogs (9), the hemiphthaloyl group was prepared by hydrolysis of the phthaloyl group at the same time as hydrolysis of the methyl ester. N d -Phthaloyl ornithine methyl ester (6b) was prepared from ornithine (3b) by a common method, as shown in Chart 1. The a-amino and carboxyl groups of ornithine were blocked by forming a chelate with Cu 2ϩ ion and phthaloylation of the w-amino group was carried out using N-ethoxycarbonylphthalimide (Nefkens' reagent: 4). 11) Removal of Cu was performed by treatment with 6 N HCl and the resulting compound 5b was esterified with dimethyl sulfite prepared from thionyl chloride and methanol to give 6b. The N w -phthaloyl methyl esters of lysine and 2,4-diaminobutyric acid (6c, 6a) were also prepared by the same procedure. Condensation of 7a, b and 6a-c in the presence of diethyl phosphorocyanidate (DEPC) and triethylamine in N,N-dimethylformamide (DMF) gave the corresponding antifolates containing N w -phthaloyl methyl esters (8a-f). Alkaline hydrolysis of the esters 8a-f afforded antifolates with N w -hemiphthaloyl 2,4-diaminobutyric acid, ornithine or lysine (9a-f). Ring-opening of the phthaloyl group was also carried out with pyrrolidine instead of aqueous sodium hydroxide. Treatment of 8c with pyrrolidine in tetrahydrofuran (THF) at room temperature for 36 h gave 10 in 85% yield. Hydrolysis of 10 with 1 eq of aqueous sodium hydroxide in MeOH provided 11 in 68% yield. N d -Z-Ornithine and free ornithine analogs (14, 15) were synthesized as shown in Chart 2. N d -Z-Ornithine ethyl ester (12) was prepared from ornithine by protection of the aamino and carboxyl groups using chelation with Cu 2ϩ ion as described above, followed by introduction of a Z-group at the d-amino group and subsequent esterification with 10% HCl in EtOH. Antifolate N d -Z-ornithine ethyl ester (13) was synthesized by coupling 7b and 12 in the presence of DEPC and triethylamine in DMF. Alkaline hydrolysis of 13 gave an antifolate with N d -Z-ornithine (14) in 89% yield, and the catalytic hydrogenation of 14 over palladium carbon in aqueous NaOH solution afforded the free ornithine-containing antifolate (15) (18) . Most methyl N w -acylornithinate-containing antifolates (20) were prepared by acylation of free amino ornithine antifolate methyl esters (19), key intermedi-ates derived from 17 by removal of the Boc-protecting group in the presence of HCl in AcOEt, using DEPC as a condensation reagent in the presence of triethylamine in DMF. The resulting esters (20) were transformed to the desired N w -acylornithine-containing antifolates (21) by alkaline hydrolysis. N w -Sulfonyl or carbamoyl ornithine-containing antifolates (23, 25) were also prepared from 19 by sulfonylation or reaction with isocyanate and hydrolysis.
In the case of carbamoyl as a masking group for the wamino group of the ornithine, the length of the side chain of amino acid seemed to be rather long. Therefore, shorter side chain compounds 30a-c were synthesized. The amino acid moieties 28a-c were synthesized from Boc-L-Glu-OMe (26b) and Boc-L-Asp-OMe (26a) by adding the intermediate isocyanate, prepared by Curtius reaction using diphenyl phosphoryl azide (DPPA), with anilines and subsequent deprotection of the Boc group. N d -Alkyl and aryl substituted ornithine analogs (36a-c) were also synthesized. Compound 36c, as a non-glutamate type g-diglutamate, was expected to show potent activity. The amino acid moieties 34a, b were synthesized from 26b. Coupling of 26b with ethyl chloroformate in the presence of triethylamine in THF gave a mixed acid anhydride, which was converted to alcohol 31 by reduction using NaBH 4 . Mesylation of 31 gave the mesylated analog, which was transformed to a more reactive iodide 32 using NaI in acetone. Reaction of 32 with aryl or alkyl amines and subsequent deprotection of the Boc group yielded the amino acids 34a, b. (Chart 3) Biological Activity and Discussion Inhibitory activities of the synthesized antifolates (9, 11, 14, 15, 18, 21, 23, 25 , 30, 36) against DHFR and murine fibrosarcoma Meth A cell growth were examined and compared with those of TNP-351 (1b), the parent compound with a glutamic acid residue ( Table 2) . Inhibition of DHFR is thought to be the primary mode of action of these compounds for three main reasons; (1) they have two amino groups on the pyrimidine ring, 3b) (2) they can not be converted to polyglutamates because antifolates with acylornithine are not substrates for folylpolyglutamate synthetase (FPGS), 12) and (3) all are weak inhibitors of thymidylate synthase, a representative folate related enzyme, with IC 50 of Ͼ10 mM (data not shown).
A free ornithine analog 15 was found to be a moderate inhibitor of DHFR comparable to TNP-351, while 15 showed much less inhibitory activity against Meth A cell growth. These results are consistent with previous observations 13) that antifolates with a positively charged d-free amino ornithine are not efficiently transported via the RFC, which is known as an anion exchange transporter. 14) On the other hand, all prepared N w -masked ornithine analogs (9, 11, 14, 18, 21, 23, 25, 30, 36) were found to be much more potent DHFR inhibitors, and strongly inhibited the growth of Meth A cells. These findings suggest that N w -masked ornithine analogs could be efficiently transported into target cells via the RFC because they have no positive charge on the amino acid moiety, and that they should strongly inhibit DHFR in the cells. With regards to the length of the spacer between the pyrrolo-[2,3-d]pyrimidine ring and the benzene ring, ethylene analogs (9a, c, e, 21k) more potently inhibited DHFR and Meth A cell growth than trimethylene analogs (9b, d, f, 21l). In the case of hemiphthaloyl ornithine analogs (9a-f), we have synthesized compounds with two to four methylenes in the side chain in order to determine the optimal length of the amino acid side chain. Trimethylene compounds (9c, d) were found to show more potent activities against DHFR than ethylene or tetramethylene compounds (9a, b, e, f). Regarding masking groups for the w-amino group of amino acids, carboxamide types (9, 11, 21) were found to have better activity than carbamate (14, 18), sulfonamide (23) and urea types (25). Among them, we noted the tendency that antifolates with an acidic group such as a carboxylic acid or a phenol on the acyl group of the ornithine show tight binding to DHFR and more potent growth inhibitory activity. These acidic functional groups may play important roles in efficient transport via the RFC, anion exchange transporter, and binding to the polyglutamate region of DHFR. Surprisingly, the aryl substituted ornithine analog (36a), but not the alkyl substituted analog (36c), was found to show very strong Meth A growth-inhibitory activity, even though the free ornithine analog was not strongly active due to poor uptake. This suggests that the RFC may allow transportation of ornithine analogs with low basicity and high lipophilicity such as aniline type compounds. In particular, analogs (9a, c, 21k) having ortho-carboxy aryl on the masking group showed the best inhibitory activities against Meth A cell growth. Antifolates containing an acylated ornithine with naphthalene or pyridine as an acyl group have never been prepared. In this study, 3-carboxy-2-naphthoyl ornithine analog (21k) was found to be twice as potent against Meth A cells as the corresponding hemiphthaloyl analog (9c).
As shown in Table 3 , the inhibitory effects of some typical compounds (9c, 21k, 23b, 36a) on the growth of MTX-sensitive and resistant CCRF-CEM cells in culture were examined in comparison with MTX in order to confirm whether the prepared antifolates were active against MTX-resistant tumor cells. The MTX-resistant cell lines used were CCRF-CEM R 1 , 15) CCRF-CEM R BO 16) and CCRF-CEM R 30/6 17) which were resistant to MTX due to an increase of DHFR level, defective transport through the RFC and decreased polyglutamylation by FPGS, respectively. All MTX-resistant CCRF-CEM cells were much less resistant to the non-glutamate antifolates compared with MTX. In particular, the o-carboxyaroyl analogs (9c, 21k) exhibited little resistance against CCRF-CEM R BO cells. These findings are consistent with previous studies showing that non-glutamate derivatives of MTX, such as PT523, showed less resistance to MTX-resistant cells with defective transport than MTX, and showed that a non-polyglutamylatable antifolate may have effective potency against MTX-resistant tumors with decreased polyglutamylation. 12) In our previous report we suggested that it might be possible to obtain novel DHFR inhibitors by replacing the g-carboxyl group with other appropriate groups while leaving the a-carboxyl group intact. In this work, we could obtain novel potent DHFR inhibitors by designing non-glutamate type antifolates with a N w -masked ornithine analog in place of glutamic acid.
Experimental
Melting points were determined on Yanagimoto micro melting point apparatus and are uncorrected. Infrared (IR) spectra were taken on JASCO IR-810 spectrometer. 1 H-NMR spectra were recorded on Varian Gemini-200 spectrometers; chemical shifts are given in ppm with tetramethylsilane as the internal standard and coupling constants (J) are measured in hertz (Hz) . Secondary ion mass spectra (SI-MS) were determined by Takeda Analytical Laboratories (Osaka, Japan) on a Hitachi M-80B instrument. Column chromatography was carried out on Silica gel 60 (E. Merck, Darmstadt, Germany).
) in H 2 O (40 ml) was added to a solution of L-ornithine (1a) (5.0 g) and NaOH (2.4 g) in H 2 O (45 ml). NaHCO 3 (3.0 g) and N-ethoxycarbonylphthalimide (7.5 g) were added and the mixture was stirred for 20 h. The resulting precipitate was collected by filtration, washed with 5 N HCl and dried in vacuo. The crude 2a was purified by recrystallization from MeOH-AcOEt to give 2a (7.08 g, 79%) as colorless needles. N e e -Phthaloyl-L-lysine Hydrochloride (2b) Compound 2b (6.01 g, 70%) as colorless needles was prepared from L-lysine hydrochloride (1b) (5.0 g) by the same method as that described for 2a.
(S)-2-Amino-4-phthaloylaminobutyric Acid Hydrochloride (2c) Compound 2c (4.44 g, 59%) as colorless needles was prepared from L-2,4-diaminobutyric acid hydrochloride (1c) (5.0 g) by the same method as that described for 2a.
Methyl
Thionyl chloride (2.6 ml) was added dropwise to MeOH (15 ml) at Ϫ10°C and the mixture was stirred for 10 min. 2a (3.0 g) was added to the mixture and the reaction mixture was stirred at room temperature for 4 d and concentrated in vacuo. The residue was triturated with Et 2 O, collected by filtration and dried in vacuo to give 3a (3.09 g, 99%) as colorless needles. Methyl N e e -Phthaloyl-L-lysinate Hydrochloride (3b) Compound 3b (3.23 g, 100%) as colorless needles was synthesized from 2b (2.76 g) by the same method as that described for 3a. Methyl (S )-2-Amino-4-phthaloylaminobutyrate Hydrochloride (3c) Compound 3c (2.83 g, 95%) as colorless needles was synthesized from 2c (2.83 g) by the same method as that described for 3a.
General Procedure for Preparation of Antifolates with N w w -Phthaloyl-L-Diamino Acid (8) Et 3 N (3.5 mmol) was added dropwise to a stirred so-
, N w -phthaloyldiamino acid methyl ester 6 (1.1 mmol) and DEPC (1.5 mmol) in dry DMF (15 ml) under ice cooling. The reaction mixture was stirred at room temperature for 4 h, then concentrated in vacuo, and the residue was dissolved in AcOEt (100 ml). The AcOEt solution was successively washed with H 2 O and brine, dried over anhydrous MgSO 4 , and concentrated in vacuo. The residue was chromatographed on silica gel (CHCl 3 : 1% NH 3 in EtOH, 20 : 1→10 : 1) to give 8.
The following compounds 8a-f were prepared. 9, 11, 14, 15, 18 and 21 1, 3 ml) at room temperature. The reaction mixture was stirred for 3 h, concentrated in vacuo and dissolved in water, and 1 N HCl (1 ml) was added to the mixture. The resulting precipitate was collected by filtration, washed with H 2 O and dried in vacuo to give 9d (80 mg, 85%) as a colorless solid.
Compounds 9a-f were prepared in a similar manner as described for the preparation of 9d. Physical properties and spectral data for compounds 9a-f are listed in Tables 1 and 4 .
Methyl 3 ml) and MeOH-THF (1 : 1, 10 ml) was hydrogenated over 10% Pd-C (65 mg) for 12 h. After the catalyst was removed, the reaction mixture was concentrated in vacuo. The residue was dissolved in H 2 O and lyophilized to give 15 (156 mg, 99%) as a colorless powder. Physical properties and spectral data for 15 are listed in Tables 1 and 4 .
Methyl (21a-l) . General Procedure A 4 N HCl solution of AcOEt (1 ml) was added to a stirred solution of 17 (0.5 mmol) in AcOEt (1 ml) at 0°C, the reaction mixture was stirred at room temperature for 20 min and concentrated in vacuo. The residue was dissolved in DMF and carboxylic acid (0.55 mmol) and DEPC (0.60 mmol) were added to the mixture. After 10 min, Et 3 N (1.5 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 2-5 h and concentrated in vacuo. The residue was chromatographed on silica gel (CHCl 3 : 8% NH 3 in EtOH, 15 : 1) to give the methyl N d -acyl-L-ornithinate. The ester was dissolved in MeOH (6 ml), and 1 N NaOH (1 ml) was added. The mixture was stirred at room temperature for 5 h, concentrated in vacuo and dissolved in H 2 O, and 1 N HCl (1 ml) was added. The resulting precipitate was collected by filtration, washed with H 2 O, and dried in vacuo to give 21a-l as a colorless solid. Physical properties and spectral data for compounds 21a-l are listed in Tables 1 and 4 . 3330, 2980, 2930, 2880, 2850, 2820, 1750, 1710, 1555, 1480, 1440 (30b) , Typical Procedure A 2 N HCl solution of AcOEt (10 ml) was added to 27b (340 mg) and the mixture was stirred for 2 h and concentrated in vacuo to give 28b. Et 3 N (0.56 ml) was added dropwise to a solution of 28b, 7a (368 mg) and DEPC (143 mg) in dry DMF (4 ml) at 0°C. The reaction mixture was stirred at room temperature for 16 h and concentrated in vacuo. 3380, 2930, 2850, 1660, 1630, 1610, 1550, 1490, 1430, 1365, 1300, 1285, 
